{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T21:53:57Z","timestamp":1770328437791,"version":"3.49.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T00:00:00Z","timestamp":1593043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Center for HIV\/AIDS, Viral Hepatitis, STD"},{"name":"Prevention Epidemiologic and Economic Modeling","award":["5U38PS004646"],"award-info":[{"award-number":["5U38PS004646"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Targeted testing and treatment (TTT) for latent tuberculosis (TB) infection (LTBI) is a recommended strategy to accelerate TB reductions and further TB elimination in the United States. Evidence on cost-effectiveness of TTT for key populations can help advance this goal.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We used a model of TB transmission to estimate the numbers of individuals who could be tested by interferon-\u03b3 release assay and treated for LTBI with 3 months of self-administered rifapentine and isoniazid (3HP) under various TTT scenarios. Specifically, we considered rapidly scaling up TTT among people who are non\u2013US-born, diabetic, living with human immunodeficiency virus (HIV), homeless or incarcerated in California, Florida, New York, and Texas\u2014states where more than half of US TB cases occur. We projected costs (from the healthcare system perspective, in 2018 dollars), 30-year reductions in TB incidence, and incremental cost-effectiveness (cost per quality-adjusted life-year [QALY] gained) for TTT in each modeled population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The projected cost-effectiveness of TTT differed substantially by state and population, while the health impact (number of TB cases averted) was consistently greatest among non\u2013US-born individuals. TTT was most cost-effective among persons with HIV (from $2828\/QALY gained in Florida to $11 265\/QALY gained in New York) and least cost-effective among people with diabetes (from $223 041\/QALY gained in California to $817 753\/QALY in New York).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The modeled cost-effectiveness of TTT for LTBI varies across states but was consistently greatest among people with HIV; moderate among people who are non\u2013US-born, incarcerated, or homeless; and least cost-effective among people with diabetes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciaa857","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T19:13:00Z","timestamp":1592593980000},"page":"e3476-e3482","source":"Crossref","is-referenced-by-count":29,"title":["Model-based Cost-effectiveness of State-level Latent Tuberculosis Interventions in California, Florida, New York, and Texas"],"prefix":"10.1093","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1440-2786","authenticated-orcid":false,"given":"Youngji","family":"Jo","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sourya","family":"Shrestha","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Gomes","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Marks","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Hill","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garrett","family":"Asay","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Dowdy","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,6,25]]},"reference":[{"key":"2021110300353825400_CIT0001","volume-title":"Reported tuberculosis in the United States, 2017","author":"Centers for Disease Control and Prevention (CDC)","year":"2018"},{"key":"2021110300353825400_CIT0002","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S1473-3099(17)30248-7","article-title":"Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA","volume":"17","author":"LoBue","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2021110300353825400_CIT0003","volume-title":"Division of tuberculosis elimination strategic plan 2016\u20132020","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"2021110300353825400_CIT0004","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1001\/jamainternmed.2017.3941","article-title":"Cost-effectiveness of testing and treatment for latent tuberculosis infection in residents born outside the United States with and without medical comorbidities in a simulation model","volume":"177","author":"Tasillo","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2021110300353825400_CIT0005","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1164\/rccm.201101-0181OC","article-title":"Priorities for screening and treatment of latent tuberculosis infection in the United States","volume":"184","author":"Linas","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2021110300353825400_CIT0006","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/aje\/kwz147","article-title":"Impact and effectiveness of state-level tuberculosis interventions in California, Florida, New York, and Texas: a model-based analysis","volume":"188","author":"Shrestha","year":"2019","journal-title":"Am J Epidemiol"},{"key":"2021110300353825400_CIT0007","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2016.11046","article-title":"Screening for latent tuberculosis infection in adults: US Preventive Services Task Force recommendation statement","volume":"316","author":"Bibbins-Domingo","year":"2016","journal-title":"JAMA"},{"key":"2021110300353825400_CIT0008","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1164\/rccm.201702-0377OC","article-title":"Comparing drivers and dynamics of tuberculosis in California, Florida, New York, and Texas","volume":"196","author":"Shrestha","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2021110300353825400_CIT0009","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1017\/S0950268897007917","article-title":"The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection","volume":"119","author":"Vynnycky","year":"1997","journal-title":"Epidemiol Infect"},{"key":"2021110300353825400_CIT0010","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12879-016-1550-y","article-title":"Initiation and completion rates for latent tuberculosis infection treatment: a systematic review","volume":"16","author":"Sandgren","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2021110300353825400_CIT0011","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/M17-1150","article-title":"Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial","volume":"167","author":"Belknap","year":"2017","journal-title":"Ann Intern Med"},{"key":"2021110300353825400_CIT0012","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial","volume":"60","author":"International Union Against Tuberculosis Committee on Prophylaxis","year":"1982","journal-title":"Bull World Health Organ"},{"key":"2021110300353825400_CIT0013","doi-asserted-by":"crossref","first-page":"926","DOI":"10.5588\/ijtld.15.1001","article-title":"Estimating tuberculosis cases and their economic costs averted in the United States over the past two decades","volume":"20","author":"Castro","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021110300353825400_CIT0014","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1186\/s13104-017-2754-y","article-title":"A systematic synthesis of direct costs to treat and manage tuberculosis disease applied to California, 2015","volume":"10","author":"Oh","year":"2017","journal-title":"BMC Res Notes"},{"key":"2021110300353825400_CIT0015","volume-title":"Cost of living index for selected U.S. cities","author":"Infoplease"},{"key":"2021110300353825400_CIT0016","volume-title":"Clinical laboratory fee schedule","author":"US Department of Health and Human Services Center for Medicare Services"},{"key":"2021110300353825400_CIT0017","volume-title":"Physician fee schedule","author":"US Department of Health and Human Services Center for Medicare Services"},{"key":"2021110300353825400_CIT0018","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.5588\/ijtld.13.0423","article-title":"Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States","volume":"17","author":"Shepardson","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021110300353825400_CIT0019","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1164\/rccm.200901-0153OC","article-title":"Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection","volume":"179","author":"Holland","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2021110300353825400_CIT0020","volume-title":".","author":"US Healthcare Cost and Utilization Project"},{"key":"2021110300353825400_CIT0021","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3201\/eid2005.131037","article-title":"Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005\u20132007","volume":"20","author":"Marks","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"2021110300353825400_CIT0022","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1183\/09031936.00216814","article-title":"Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion","volume":"45","author":"Sotgiu","year":"2015","journal-title":"Eur Respir J"},{"key":"2021110300353825400_CIT0023","doi-asserted-by":"crossref","first-page":"e20755","DOI":"10.1371\/journal.pone.0020755","article-title":"Assessing tuberculosis case fatality ratio: a meta-analysis","volume":"6","author":"Straetemans","year":"2011","journal-title":"PLoS One"},{"key":"2021110300353825400_CIT0024","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/heapol\/czl018","article-title":"Calculating QALYs, comparing QALY and DALY calculations","volume":"21","author":"Sassi","year":"2006","journal-title":"Health Policy Plan"},{"key":"2021110300353825400_CIT0025","first-page":"931","article-title":"Causes and costs of hospitalization of tuberculosis patients in the United States","volume":"4","author":"Taylor","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021110300353825400_CIT0026","volume-title":"Actuarial life table","author":"US Social Security Administration"},{"key":"2021110300353825400_CIT0027","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1016\/S2214-109X(15)00069-8","article-title":"Disability weights for the Global Burden of Disease 2013 Study","volume":"3","author":"Salomon","year":"2015","journal-title":"Lancet Glob Health"},{"key":"2021110300353825400_CIT0028","doi-asserted-by":"crossref","first-page":"e5080","DOI":"10.1371\/journal.pone.0005080","article-title":"Personal and societal health quality lost to tuberculosis","volume":"4","author":"Miller","year":"2009","journal-title":"PLoS One"},{"key":"2021110300353825400_CIT0029","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.2337\/dc11-2478","article-title":"Health utility scores for people with type 2 diabetes in U.S. managed care health plans: results from Translating Research Into Action for Diabetes (TRIAD)","volume":"35","author":"Zhang","year":"2012","journal-title":"Diabetes Care"},{"key":"2021110300353825400_CIT0030","volume-title":"TB in California: 2018 snapshot","author":"California Department of Public Health"},{"key":"2021110300353825400_CIT0031","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2105\/AJPH.2018.304503","article-title":"Tuberculosis incidence among populations at high risk in California, Florida, New York, and Texas, 2011-2015","volume":"108","author":"Cherng","year":"2018","journal-title":"Am J Public Health"},{"key":"2021110300353825400_CIT0032","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/aje\/kwt246","article-title":"Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup","volume":"179","author":"Shea","year":"2014","journal-title":"Am J Epidemiol"},{"key":"2021110300353825400_CIT0033","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/cid\/ciw778","article-title":"Official American Thoracic Society\/Infectious Diseases Society of America\/Centers for Disease Control and Prevention Clinical Practice Guidelines: diagnosis of tuberculosis in adults and children","volume":"64","author":"Lewinsohn","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021110300353825400_CIT0034","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S2213-8587(14)70110-X","article-title":"Clinical management of concurrent diabetes and tuberculosis and the implications for patient services","volume":"2","author":"Riza","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2021110300353825400_CIT0035","doi-asserted-by":"crossref","first-page":"e0214532","DOI":"10.1371\/journal.pone.0214532","article-title":"Outlook for tuberculosis elimination in California: an individual-based stochastic model","volume":"14","author":"Goodell","year":"2019","journal-title":"PLoS One"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa857\/33556630\/ciaa857.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/9\/e3476\/41057915\/ciaa857.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/9\/e3476\/41057915\/ciaa857.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:38:41Z","timestamp":1635899921000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/9\/e3476\/5862678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,25]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,6,25]]},"published-print":{"date-parts":[[2021,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa857","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2020,6,25]]}}}